Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B)
2024International Journal of Infectious DiseasesJournalOpen access
10.1016/j.ijid.2024.107161Full text1 citations